Whether this is subtype-specific or dose-specific, these results highlight the complexity involved in analyzing the anti-tumor effects of IFNα and emphasize how critical it is to understand the mechanisms that underpin these differential anti-cancer responses. The gene discussed is IFNA1; the disease is neoplasm.